Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives
摘要:
In this report we disclose the synthesis, vasodilatory activity, and identification of bioactive conformation of new N-acylhydrazone and N-methyl-N-acylhydrazone derivatives, structurally designed by bioisosteric replacements of previously described cardioactive compounds LASSBio-294 and its N-methyl derivative LASSBio-785. Some of these novel derivatives presented improved vasorelaxant properties, being new cardiovascular drug candidates. (C) 2009 Elsevier Masson SAS. All rights reserved.
Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives
摘要:
In this report we disclose the synthesis, vasodilatory activity, and identification of bioactive conformation of new N-acylhydrazone and N-methyl-N-acylhydrazone derivatives, structurally designed by bioisosteric replacements of previously described cardioactive compounds LASSBio-294 and its N-methyl derivative LASSBio-785. Some of these novel derivatives presented improved vasorelaxant properties, being new cardiovascular drug candidates. (C) 2009 Elsevier Masson SAS. All rights reserved.
Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives
作者:Arthur E. Kümmerle、Juliana M. Raimundo、Carla M. Leal、Givanildo S. da Silva、Tatiane L. Balliano、Mariano A. Pereira、Carlos A. de Simone、Roberto T. Sudo、Gisele Zapata-Sudo、Carlos A.M. Fraga
DOI:10.1016/j.ejmech.2009.04.044
日期:2009.10
In this report we disclose the synthesis, vasodilatory activity, and identification of bioactive conformation of new N-acylhydrazone and N-methyl-N-acylhydrazone derivatives, structurally designed by bioisosteric replacements of previously described cardioactive compounds LASSBio-294 and its N-methyl derivative LASSBio-785. Some of these novel derivatives presented improved vasorelaxant properties, being new cardiovascular drug candidates. (C) 2009 Elsevier Masson SAS. All rights reserved.